Trial reportDigestive diseases and sciences2004
High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study.
Trial report in Digestive diseases and sciences, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 52 citations in OpenAlex.
- Adherent-invasiveFrontiers in microbiology · 2023Article
- Gastrointestinal dysbiosis and Escherichia coli pathobionts in inflammatory bowel diseases.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2022Article
- Phylogrouping and characterization ofFrontiers in medicine · 2022Article
- Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease.PloS one · 2018Article
- IBD Serology and Disease Outcomes in African Americans With Crohn's Disease.Inflammatory bowel diseases · 2017Article
- Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases.Gastroenterology · 2017Review
- Microbiology, genomics, and clinical significance of the Pseudomonas fluorescens species complex, an unappreciated colonizer of humans.Clinical microbiology reviews · 2014Review
- IBD-what role do Proteobacteria play?Nature reviews. Gastroenterology & hepatology · 2012Review
- Current and future role of biomarkers in Crohn's disease risk assessment and treatment.Clinical and experimental gastroenterology · 2011Article
- Distinct IFNG methylation in a subset of ulcerative colitis patients based on reactivity to microbial antigens.Inflammatory bowel diseases · 2011Article
- Microbial host interactions in IBD: implications for pathogenesis and therapy.Current gastroenterology reports · 2007Review
- Utility of serological markers in inflammatory bowel diseases: gadget or magic?World journal of gastroenterology · 2007Review
- Antibiotic therapy for Crohn's disease: a review.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
In Crohn's disease, antibiotics are used with variable efficacy, suggesting that some patients are more likely to respond. The aim of this study was to determine whether Crohn's patients with predominant serum antibody reactivity toward bacterial antigens OmpC and/or I2 were more likely to achieve remission with antibiotics. Patients with ileal or ileal with right-sided colonic Crohn's disease were studied in a double-blind trial of budesonide alone or budesonide plus metronidazole and ciprofloxacin. In the budesonide plus metronidazole and ciprofloxacin group, patients with OmpC/I2 predominant profiles had the highest remission rate, whereas the group with no antibody predominant profiles had the lowest rate. In the budesonide group, patients with the OmpC/I2 predominant profile had the lowest remission rate, and the no-antibody group rate was higher. Although not statistically significant, these results support further testing to determine whether predominant serum reactivity to certain bacterial antigens may be a marker for efficacious use of antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.